Lump-Sum Royalty vs Running Royalty: Which Licensing Approach Succeeds in China?
In 2024, 62% of China cross-border licensing deals under ¥10 million used lump-sum structures, yet running royalties dominated 73% of pharmaceutical and biotech agreements above ¥50 million. The choice between a 一次性许可费 (lump-sum royalty, yīcì xìng xǔkě fèi) and a 分期许可费 (running royalty, fēnqí xǔkě fèi) is not academic — it determines tax exposure, partner behavior, and exit flexibility. A 许可协议 (license agreement, xǔkě xiéyì) can shift from a straightforward cash transaction to a decade-long revenue-sharing partnership based entirely on this decision. For foreign executives entering China, understanding which model aligns with your IP strength, market uncertainty, and partner trust is the single most consequential licensing choice you will make.
Defining the Two Royalty Models in China’s Context
A lump-sum royalty structure requires the licensee to pay a fixed, one-time fee — often structured in installments tied to milestones such as regulatory approval or first commercial sale — for the entire license term. China’s State Administration of Taxation (SAT) treats lump-sum payments as 无形资产转让 (intangible asset transfer, wúxíng zīchǎn zhuǎnràng) income, subject to withholding tax at 10% for royalties under the China–US double taxation treaty, or 6% VAT on the gross amount depending on the service classification. From 2019 to 2024, the average lump-sum royalty for a mid-market technology patent in China was ¥4.8 million, with typical payment terms split 40% upfront and 60% upon regulatory filing.
A running royalty, by contrast, ties payments to a percentage of net sales, units sold, or per-use metrics over the license life. China’s typical running royalty rate for industrial patents ranges from 2% to 6% of net sales, while pharmaceutical royalties stretch from 5% to 15% depending on the drug’s clinical stage. Running royalties are treated as 特许权使用费 (royalty income, tèxǔ quán shǐyòng fèi) under Chinese tax law, attracting a 10% withholding tax on gross payments (reduced under most tax treaties) plus 6% VAT. The key difference is that running royalties create a long-term taxable presence in China, potentially triggering permanent establishment (PE) risk under Article 5 of the China Model Double Taxation Agreement if the licensor provides ongoing technical services.
Between 2020 and 2023, the proportion of China inbound licensing deals using lump-sum structures fell from 48% to 34%, while running royalties rose from 52% to 66%, driven by complex pharmaceutical and software deals where post-approval revenue is highly uncertain. However, for small to mid-size foreign firms (under ¥50 million annual China revenue), lump-sum remains the preferred model because it avoids ongoing compliance and monitoring costs that can add ¥120,000–¥300,000 per year in legal and auditing expenses.
Financial, Tax, and Currency Control Implications
The financial impact of choosing the wrong model can be severe. A lump-sum royalty provides immediate cash repatriation via China’s SAFE (State Administration of Foreign Exchange) channels, typically processed within 15–25 business days if the license is registered with the Ministry of Commerce (MOFCOM) and IP office. The one-time withholding tax of 10% (or lower under treaty) is final — no future exposure. For a ¥5 million lump-sum deal, the net after-tax return to the foreign licensor is approximately ¥4.5 million if the reduced treaty rate applies, or ¥4.25 million at the standard 15% domestic rate if treaty benefits are not claimed.
Running royalties, while smaller per payment, create a recurring tax and compliance burden. Each quarterly or annual royalty payment requires a separate tax filing, foreign exchange application, and support documentation — including audited sales statements from the Chinese licensee. Over a 10-year deal with ¥3 million annual royalties, the cumulative tax leakage at 10% withholding is ¥3 million, but administrative costs add another ¥1.2–¥2.4 million for compliance, audits, and potential transfer pricing adjustments. China’s tax authorities have increasingly scrutinized running royalty payments under 特别纳税调整 (special tax adjustment, tèbié nàshuì tiáozhěng) rules, demanding proof that the royalty rate reflects arm’s length pricing under BEPS Action 8–10 guidelines. Between 2021 and 2024, China’s tax bureaus issued 37 transfer pricing adjustments on cross-border royalty payments, with average tax assessments of ¥2.1 million per case.
Currency control is another critical factor. Lump-sum royalties are easier to repatriate because they are a single, defined transaction. Running royalties face higher rejection rates at Chinese banks: in 2023, approximately 12% of outbound royalty remittances were delayed or blocked due to incomplete documentation or mismatch between the license agreement and the supporting invoices. Each delay can stretch 30–60 days, creating cash flow uncertainty for the foreign licensor.
Risk Allocation, Partner Behavior, and Exit Flexibility
The lump-sum model shifts virtually all commercial risk to the licensee. The Chinese partner pays a fixed price upfront and must recoup their investment through sales, manufacturing, or sublicensing. This structure is ideal when the foreign licensor has strong IP protection, limited interest in ongoing operations, and a desire to exit China cleanly. However, it also means the foreign firm captures zero upside if the Chinese market explodes — a risk that cost one US medtech company an estimated ¥120 million in foregone revenue when their ¥8 million lump-sum licensed technology generated ¥2 billion in sales over five years.
Running royalties align incentives: both parties share upside and downside. The licensor earns more if the product succeeds, motivating them to provide technical support, improvement patents, and market access assistance. In practice, running royalty deals in China between 2020 and 2024 had an average 18% higher renewal rate than lump-sum deals, because the ongoing relationship fostered trust and collaboration. However, running royalties require robust audit rights — without them, Chinese licensees under-report sales by an estimated 10–25% according to a 2023 survey of 82 cross-border licensing disputes in China. The legal cost to audit and enforce underpayment claims averages ¥450,000 per case, and takes 14–24 months to resolve through CIETAC arbitration.
Exit flexibility also differs. A lump-sum license can be terminated with a single notice if the licensee fails to pay the full amount — typically within 60–90 days. Running royalty agreements are harder to terminate because the licensor must prove ongoing breach of contract, non-payment, or material failure to commercialize. In 2022, a German chemical company spent ¥3.8 million in legal fees to terminate a running royalty agreement where the Chinese partner had halted production but refused to surrender the license — a risk that does not exist with lump-sum deals.
Industry-Specific Trends and Data (2019–2024)
| Industry | Lump-Sum Share (2024) | Running Royalty Share (2024) | Typical Lump-Sum Range | Typical Running Royalty Rate | Avg Deal Duration |
|---|---|---|---|---|---|
| Pharmaceutical & Biotech | 22% | 78% | ¥8M–¥30M | 5%–15% of net sales | 12–18 years |
| Industrial Manufacturing | 58% | 42% | ¥2M–¥10M | 2%–5% of net sales | 5–10 years |
| Software & SaaS | 45% | 55% | ¥1M–¥8M | 15%–30% of subscription revenue | 3–7 years |
| Consumer Goods & Brand Licensing | 72% | 28% | ¥3M–¥20M | 3%–8% of wholesale revenue | 3–5 years |
| Clean Energy & EV Batteries | 38% | 62% | ¥5M–¥25M | 2%–4% of unit price | 8–15 years |
Source: China Licensing Data Consortium (CLDC) 2024 Annual Report, based on 1,247 recorded cross-border licensing transactions.
The table reveals a clear sectoral divide. Pharmaceutical and biotech overwhelmingly prefer running royalties because blockbuster sales are unpredictable — a ¥10 million lump-sum would be a bargain if the drug achieves ¥1 billion in China sales. Conversely, consumer goods and brand licensing favor lump-sum because brand value is more stable, and the foreign owner typically wants minimal operational involvement. Industrial manufacturing sits in the middle, with lump-sum slightly dominant because technology lifecycles are shorter (5–7 years) and Chinese manufacturers often demand fully paid-up licenses for production certainty.
Decision Framework: Matching Model to Your Situation
If your IP is early-stage, unproven in China, or requires extensive local adaptation, choose running royalty. The lower upfront barrier makes the deal attractive to Chinese partners who are risk-averse, and you retain upside if the technology succeeds. This is the standard approach for pre-clinical pharmaceutical compounds, prototype software, or novel manufacturing processes that need 2–3 years of local validation.
If your IP is mature, patent-protected, and you want a clean exit from China operations, choose lump-sum royalty. Immediate cash repatriation, minimal compliance burden, and zero ongoing relationship risk make this ideal for established chemical processes, mature industrial designs, or brand rights where you do not want to audit Chinese sales. This model also suits foreign firms that lack in-house China legal resources or are winding down their China presence.
If you are uncertain about your partner’s trustworthiness or audit capabilities, choose lump-sum with milestone installments. Structure the ¥10 million fee as ¥3 million upfront, ¥4 million upon regulatory approval, and ¥3 million after first commercial sale. This hybrid model reduces your risk without requiring the full monitoring infrastructure that a pure running royalty demands.
For most foreign executives, the safe default in 2024 China is lump-sum for deals under ¥8 million, and running royalty for deals above ¥30 million where ongoing collaboration is essential. Between ¥8 million and ¥30 million, use the hybrid milestone approach and negotiate a minimum annual royalty clause to ensure the licensee commercializes diligently.
Three Critical Pitfalls to Avoid
Case Study: MedTech China’s ¥15 Million Licensing Split
A US cardiovascular device company licensed its stent coating technology to a Suzhou manufacturer in 2021. The deal was structured as ¥15 million lump-sum, paid as ¥5 million upfront, ¥5 million upon NMPA approval (obtained in 18 months), and ¥5 million after first commercial sale (achieved in 25 months). The Chinese partner then launched the coated stent at ¥18,000 per unit and sold 12,000 units in the first year, generating ¥216 million in revenue. The US firm received its final ¥5 million payment 25 months after signing — a total net return of approximately ¥13.5 million after withholding tax, with zero ongoing exposure.
Had the US firm chosen a running royalty of 6%, they would have earned ¥12.96 million in the first year alone (6% × ¥216 million), plus continuing revenue in subsequent years. The opportunity cost of the lump-sum choice was ¥11.46 million in foregone year-one royalties alone. However, the US firm’s CFO noted that the lump-sum structure allowed them to exit China completely, avoid hiring a local compliance team (estimated cost ¥800,000/year), and eliminate currency control risk. For a firm with no China office and a focus on the US market, the lump-sum was strategically correct — but the numbers show how massively running royalties can outperform when a product succeeds beyond expectations.
NEXT STEPS
- Run a royalty model simulation — Use our China Licensing Royalty Calculator to model tax, timing, and exit outcomes for both structures based on your deal size and industry.
- Negotiate transfer pricing protection — Before signing any running royalty agreement, read our Transfer Pricing Compliance Guide for Royalty Agreements to avoid BEPS adjustments and back-tax assessments.
- Draft a hybrid milestone agreement — See our Sample China License Agreement with Lump-Sum and Running Royalty Clauses for a ready-to-adapt template with audit, termination, and currency control provisions.
— China Gateway 360 —
Remote China market entry support, built around execution.
